ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Average Target Price from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average rating of “Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $77.71.

Several equities research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Raymond James increased their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Finally, Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd.

ANI Pharmaceuticals Stock Down 2.0 %

Shares of ANIP opened at $54.41 on Friday. The company has a market capitalization of $1.14 billion, a P/E ratio of -98.93 and a beta of 0.73. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The business’s 50 day simple moving average is $57.36 and its 200-day simple moving average is $59.56. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The business’s revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,231 shares of company stock worth $2,434,286. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Texas Permanent School Fund Corp boosted its holdings in shares of ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 178 shares during the period. Louisiana State Employees Retirement System boosted its stake in ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System increased its holdings in ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares during the period. Finally, New York State Teachers Retirement System raised its stake in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.